Domperidone is NOT appropriate for treating achalasia
Domperidone has no role in the treatment of achalasia and should not be used for this condition. The established treatments for achalasia are mechanical disruption of the lower esophageal sphincter through pneumatic dilation (PD), laparoscopic Heller myotomy (LHM), or per-oral endoscopic myotomy (POEM) 1, 2, 3.
Why Domperidone Doesn't Work for Achalasia
Achalasia is fundamentally a disorder of impaired lower esophageal sphincter (LES) relaxation coupled with loss of organized esophageal peristalsis due to degeneration of the myenteric plexus 3. The pathophysiology requires mechanical disruption of the sphincter—not prokinetic medication.
Domperidone is a dopamine D2-receptor antagonist used as a prokinetic agent for gastroparesis, where it enhances gastric motility 4, 5, 6, 7. However, in achalasia:
- The problem is a non-relaxing sphincter, not poor motility
- There is absent peristalsis in the esophageal body that cannot be restored by prokinetics
- The esophagus needs mechanical opening, not enhanced contractility
Appropriate Treatments for Achalasia
The evidence-based treatment options are 1, 2, 3:
First-Line Definitive Therapies:
- POEM (per-oral endoscopic myotomy) - particularly preferred for Type III achalasia where longer myotomy is needed
- Laparoscopic Heller myotomy (LHM) - comparable efficacy to POEM for most achalasia subtypes
- Pneumatic dilation (PD) - effective but may require repeat procedures
Treatment Selection Based on Achalasia Subtype:
- Type II achalasia: Best treatment outcomes with any modality
- Type III achalasia: POEM is preferred due to ability to perform longer myotomy (averaging 17.2 cm) to address obstructive contractility of the distal esophagus 2
- Type I achalasia: POEM or LHM are comparable options
Critical Safety Note About Domperidone
Even if domperidone were theoretically considered, it carries significant cardiac risks that make it problematic:
- Not FDA-approved for any indication in humans in the United States 8
- Causes hERG channel inhibition and QT prolongation 9
- Contraindicated in patients with pre-existing QT prolongation, those on CYP3A4 inhibitors, or with electrolyte abnormalities 9
- Side effects include palpitations, prolonged QTc, chest pain, and arrhythmias 4, 7
Post-Treatment Management
After appropriate mechanical treatment (POEM or LHM), patients require:
- Pharmacologic acid suppression with PPIs in the immediate post-procedure period due to 41-56% risk of abnormal acid exposure 1
- Follow-up endoscopy and/or pH monitoring at 6-12 months 1
- Long-term surveillance given the 5-fold increased risk of esophageal cancer in achalasia patients 1
Bottom line: Refer patients with achalasia to a gastroenterologist experienced in performing or coordinating definitive mechanical therapies (POEM, LHM, or PD). Do not prescribe domperidone for this condition.